UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development

Current pharmaceutical design, 2013, Vol.19 (3), p.366-376

2013

Volltextzugriff (PDF)

Early dynamics of circulating tumor DNA predict clinical response to immune checkpoint inhibitors in metastatic renal cell carcinoma

International journal of urology, 2022-05, Vol.29 (5), p.462-469

2022

Volltextzugriff (PDF)

Shikonin, dually functions as a proteasome inhibitor and a necroptosis inducer in multiple myeloma cells

International journal of oncology, 2015-03, Vol.46 (3), p.963-972

2015

Volltextzugriff (PDF)

Detection of ERBB2 (HER2) Gene Amplification Events in Cell-Free DNA and Response to Anti-HER2 Agents in a Large Asian Cancer Patient Cohort

Frontiers in oncology, 2019-04, Vol.9, p.212-212

2019

Volltextzugriff (PDF)

A Nonfucosylated Anti-HER2 Antibody Augments Antibody-Dependent Cellular Cytotoxicity in Breast Cancer Patients

Clinical cancer research, 2007-03, Vol.13 (6), p.1875-1882

2007

Volltextzugriff (PDF)

Systemic Distribution of Steroid Sulfatase and Estrogen Sulfotransferase in Human Adult and Fetal Tissues

The journal of clinical endocrinology and metabolism, 2002-12, Vol.87 (12), p.5760-5768

2002

Volltextzugriff (PDF)

Selective KIT inhibitor KI-328 and HSP90 inhibitor show different potency against the type of KIT mutations recurrently identified in acute myeloid leukemia

International journal of hematology, 2010-11, Vol.92 (4), p.624-633

2010

Volltextzugriff (PDF)

A novel steroidal selective steroid sulfatase inhibitor KW-2581 inhibits sulfated-estrogen dependent growth of breast cancer cells in vitro and in animal models

Breast cancer research and treatment, 2007-12, Vol.106 (2), p.215-227

2007

Volltextzugriff (PDF)

RSK2Ser227 at N-Terminal Kinase Domain Is a Potential Therapeutic Target for Multiple Myeloma

Molecular cancer therapeutics, 2012-12, Vol.11 (12), p.2600-2609

2012

Volltextzugriff (PDF)

A Novel FLT3 Inhibitor FI-700 Selectively Suppresses the Growth of Leukemia Cells with FLT3 Mutations

Clinical cancer research, 2007-08, Vol.13 (15), p.4575-4582

2007

Volltextzugriff (PDF)

Synthesis and Antitumor Activity of Novel O-Carbamoylmethyloxime Derivatives of Radicicol

Journal of medicinal chemistry, 2003-06, Vol.46 (12), p.2534-2541

2003

Volltextzugriff (PDF)

Role of steroid sulfatase in local formation of estrogen in post-menopausal breast cancer patients

Journal of steroid biochemistry and molecular biology, 2003-09, Vol.86 (3), p.455-460

2003

Volltextzugriff (PDF)

New Molecular and Biological Mechanism of Antitumor Activities of KW-2478, a Novel Nonansamycin Heat Shock Protein 90 Inhibitor, in Multiple Myeloma Cells

Clinical cancer research, 2010-05, Vol.16 (10), p.2792-2802

2010

Volltextzugriff (PDF)

A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response

Blood, 2009-04, Vol.113 (17), p.3938-3946

2009

Volltextzugriff (PDF)

KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation

Blood, 2009-08, Vol.114 (8), p.1607-1617

2009

Volltextzugriff (PDF)

Molecular target therapeutics of cancer and translational research

Folia Pharmacologica Japonica, 2011, Vol.137(6), pp.241-244

Shiotsu, Yukimasa

2011

Volltextzugriff (PDF)

Abstract 262: Heat Map Analysis, a new integrated pathway scoring system for cancer genome profiling

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.262-262

2023

Volltextzugriff (PDF)

Hsp90 Inhibitors as Anti-Cancer Agents, from Basic Discoveries to Clinical Development

Current pharmaceutical design, 2012-11, Vol.19 (3), p.366-376

2012

Volltextzugriff (PDF)

Comprehensive genomic profiling of circulating cell-free DNA (cfDNA) distinguishes focal amplification (amp) from aneuploidy among MET amps in diverse advanced cancer types

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.3046-3046

2019

Volltextzugriff (PDF)

RSK2(Ser227) at N-terminal kinase domain is a potential therapeutic target for multiple myeloma

Molecular cancer therapeutics, 2012-12, Vol.11 (12), p.2600-2609

2012

Volltextzugriff (PDF)

Development of radicicol analogues

Current cancer drug targets, 2003-10, Vol.3 (5), p.359-369

2003

Volltextzugriff (PDF)

S5-2. The Role of Biomarker in the Process of Research and Development of New Cancer Therapeutics

Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics, 2009, Vol.40(2), pp.21S-22S

SHIOTSU, Yukimasa

2009

Volltextzugriff (PDF)

Clinical Application of Genomic Profiling With Circulating Tumor DNA for Management of Advanced Non–Small-cell Lung Cancer in Asia

Clinical lung cancer, 2018-09, Vol.19 (5), p.e601-e608

2018

Volltextzugriff (PDF)

Expression level of enzymes related to in situ estrogen synthesis and clinicopathological parameters in breast cancer patients

The Journal of steroid biochemistry and molecular biology, 2009-02, Vol.113 (3), p.195-201

2009

Volltextzugriff (PDF)

Abstract 920: KW-2450, a novel IGF-1R/IR inhibitor, enhances the antitumor effect of lapatinib, letrozole or 4-hydroxy-tamoxifen in breast cancer cells

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.920-920

2013

Volltextzugriff (PDF)

1 – 25 von 56

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(53)
Mit Volltextzugriff
(50)

Publikationsform

Artikel
(56)

Sprache

Englisch
(47)
Japanisch
(10)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development

Early dynamics of circulating tumor DNA predict clinical response to immune checkpoint inhibitors in metastatic renal cell carcinoma

Shikonin, dually functions as a proteasome inhibitor and a necroptosis inducer in multiple myeloma cells

Detection of ERBB2 (HER2) Gene Amplification Events in Cell-Free DNA and Response to Anti-HER2 Agents in a Large Asian Cancer Patient Cohort

A Nonfucosylated Anti-HER2 Antibody Augments Antibody-Dependent Cellular Cytotoxicity in Breast Cancer Patients

Systemic Distribution of Steroid Sulfatase and Estrogen Sulfotransferase in Human Adult and Fetal Tissues

Selective KIT inhibitor KI-328 and HSP90 inhibitor show different potency against the type of KIT mutations recurrently identified in acute myeloid leukemia

A novel steroidal selective steroid sulfatase inhibitor KW-2581 inhibits sulfated-estrogen dependent growth of breast cancer cells in vitro and in animal models

RSK2Ser227 at N-Terminal Kinase Domain Is a Potential Therapeutic Target for Multiple Myeloma

A Novel FLT3 Inhibitor FI-700 Selectively Suppresses the Growth of Leukemia Cells with FLT3 Mutations

Synthesis and Antitumor Activity of Novel O-Carbamoylmethyloxime Derivatives of Radicicol

Role of steroid sulfatase in local formation of estrogen in post-menopausal breast cancer patients

New Molecular and Biological Mechanism of Antitumor Activities of KW-2478, a Novel Nonansamycin Heat Shock Protein 90 Inhibitor, in Multiple Myeloma Cells

A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response

KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation

Molecular target therapeutics of cancer and translational research

Abstract 262: Heat Map Analysis, a new integrated pathway scoring system for cancer genome profiling

Hsp90 Inhibitors as Anti-Cancer Agents, from Basic Discoveries to Clinical Development

Comprehensive genomic profiling of circulating cell-free DNA (cfDNA) distinguishes focal amplification (amp) from aneuploidy among MET amps in diverse advanced cancer types

RSK2(Ser227) at N-terminal kinase domain is a potential therapeutic target for multiple myeloma

Development of radicicol analogues

S5-2. The Role of Biomarker in the Process of Research and Development of New Cancer Therapeutics

Clinical Application of Genomic Profiling With Circulating Tumor DNA for Management of Advanced Non–Small-cell Lung Cancer in Asia

Expression level of enzymes related to in situ estrogen synthesis and clinicopathological parameters in breast cancer patients

Abstract 920: KW-2450, a novel IGF-1R/IR inhibitor, enhances the antitumor effect of lapatinib, letrozole or 4-hydroxy-tamoxifen in breast cancer cells

Suchergebnisse filtern